Quarterly ResultMay 14, 2026, 04:15 PM
Arcadia Biosciences Q1 Net Loss $4.4M; Going Concern Doubt
AI Summary
Arcadia Biosciences reported a net loss of $4.4 million for the first quarter of 2026, a significant decline from a net income of $2.6 million in the prior year's quarter, with product revenues decreasing to $1.1 million. The company's financial statements indicate substantial doubt about its ability to continue as a going concern due to insufficient cash and ongoing operating losses. During the quarter, Arcadia completed a January 2026 Inducement Offer, generating $2.1 million in proceeds but incurring a $2.9 million loss related to the offer.
Key Highlights
- Arcadia Biosciences reported a net loss of $4.4 million for Q1 2026, compared to net income of $2.6 million in Q1 2025.
- Basic net loss per share was $2.11 for Q1 2026, down from income of $1.90 in Q1 2025.
- Product revenues decreased to $1.1 million in Q1 2026 from $1.2 million in Q1 2025.
- The company raises substantial doubt about its ability to continue as a going concern.
- Cash and cash equivalents were $954,000 as of March 31, 2026.
- Net cash used in operating activities was $1.1 million for Q1 2026.
- The January 2026 Inducement Offer generated $2.1 million in proceeds but resulted in a $2.9 million loss.
- Accumulated deficit reached $285.6 million as of March 31, 2026.
Price Impact
More from RKDA